HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Microbot Medical (NASDAQ:MBOT) and maintained an $8 price target.
October 18, 2023 | 11:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Microbot Medical and maintained an $8 price target.
The reiteration of a 'Buy' rating and maintenance of an $8 price target by HC Wainwright & Co. indicates a positive outlook for Microbot Medical. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100